Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma
نویسندگان
چکیده
Aims: Programmed cell death ligand 1 (PD-L1) is the of programmed (PD-1), which a host immunity inhibitory receptor. Expression PD-L1 in diverse tumor types has been widely discussed, while there little research about intrinsic-PD-1. Phospho-S6 (p-S6) an important downstream effector PI3K/AKT/mTOR pathway. Our study was focused on investigating expression cancer cell-intrinsic PD-1, and p-S6 proteins aimed to illustrate their relationship clinical significances nasopharyngeal carcinoma (NPC). Methods: The tissues NPC, non-cancerous epithelia, primary matching metastatic lesion detected by immunohistochemistry. Results: co-expression PD-1 were significantly higher NPC (all P<0.05). paired increased P<0.01). patients with positive showed overall survival rate (P =0.035). However, lower =0.031, P=0.044, respectively). Interestingly, had (P=0.042). Multivariate Cox proportional hazard regression analysis confirmed that independent prognostic factors for patients. Conclusions: associates proteins, might serve as good biomarker, could be poor biomarker
منابع مشابه
PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load
Programmed death-1 (PD-1) is an immunosuppressive receptor functionally bound with programmed death-ligand 1 (PD-L1), which has been reported in various malignancies. However, only a few studies are available for the clinical significance of PD-1/PD-L1 in nasopharyngeal carcinoma (NPC). In this study, we aim to investigate alterations in PD-1/PD-L1 by using immunohistochemistry analysis in a co...
متن کاملPD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
While the prognosis of gastric cancer (GC) remains poor, PD-1 and PD-L1/L2 are promising prognostic biomarkers. We evaluated PD-1 and PD-L1/L2 expression in tumor cells (TCs) and tumor-infiltrating immune cells (TIICs). We determined the Helicobacter pylori (Hp) and Epstein-Barr virus (EBV) infection status in a GC cohort (n=340), then analyzed the relationship between the expression of PD-1, P...
متن کاملBasal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic basal cell carcinoma, however, has largely gone untested. Because PD-Ligand-1 (PD-L1) expression in other tumor types has been associated with response to anti-PD-1, we investigated the e...
متن کاملCo-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) carries a high potential for metastasis and immune escape, with a great risk of relapse after primary treatment. Through analysis of whole genome expression profiling data in NPC samples, we found that the expression of a long non-coding RNA (lncRNA), actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1), is significantly correlated with the immune escap...
متن کاملPD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Monoclonal antibodies that target the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) axis have antitumor activity against multiple cancers. The presence of sarcomatoid differentiation in renal cell carcinoma (RCC) is associated with resistance to targeted therapy and poor responses to IL2 immunotherapy. Given the aggressive nature of RCC with sarcomatoid differentiation and the exc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer
سال: 2021
ISSN: ['1837-9664']
DOI: https://doi.org/10.7150/jca.60739